150 related articles for article (PubMed ID: 36170166)
21. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
[TBL] [Abstract][Full Text] [Related]
22. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
23. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
[TBL] [Abstract][Full Text] [Related]
24. Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis.
Cheng JM; Canzoniero J; Lee S; Soni S; Mangini N; Santa-Maria CA
Breast Cancer Res Treat; 2023 Jun; 199(2):389-397. PubMed ID: 37002487
[TBL] [Abstract][Full Text] [Related]
25. Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer.
Morigi C
Ecancermedicalscience; 2017; 11():732. PubMed ID: 28491135
[TBL] [Abstract][Full Text] [Related]
26.
Lee A; Moon BI; Kim TH
Ann Lab Med; 2020 Mar; 40(2):114-121. PubMed ID: 31650727
[TBL] [Abstract][Full Text] [Related]
27. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
[TBL] [Abstract][Full Text] [Related]
28. [PARP inhibitors in breast cancer: Current clinical development and perspectives].
Robbe J; Moretta J; Vicier C; Sabatier R; Noguès C; Gonçalves A
Bull Cancer; 2020 Oct; 107(10):1024-1041. PubMed ID: 33004179
[TBL] [Abstract][Full Text] [Related]
29. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
30. Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers.
Downs B; Sherman S; Cui J; Kim YC; Snyder C; Christensen M; Luo J; Lynch H; Wang SM
Eur J Cancer; 2019 Jan; 107():68-78. PubMed ID: 30551077
[TBL] [Abstract][Full Text] [Related]
31. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
32. Integrating PARP inhibitors into the management of breast cancer: where are we?
Azim HA; Kassem L; Azim H
Chin Clin Oncol; 2021 Jan; 10(5):50. PubMed ID: 33440946
[TBL] [Abstract][Full Text] [Related]
33. Ataxia-telangiectasia gene (
Jerzak KJ; Mancuso T; Eisen A
Curr Oncol; 2018 Apr; 25(2):e176-e180. PubMed ID: 29719442
[TBL] [Abstract][Full Text] [Related]
34. Pathology of hereditary breast cancer.
Da Silva L; Lakhani SR
Mod Pathol; 2010 May; 23 Suppl 2():S46-51. PubMed ID: 20436502
[TBL] [Abstract][Full Text] [Related]
35. Factors that influence the management recommendations breast surgeons provide to women with pathogenic variants in moderate penetrance breast cancer susceptibility genes.
Vanderwal A; Lewis J; Basil J; Atzinger C; Widmeyer K
J Genet Couns; 2023 Jun; 32(3):674-684. PubMed ID: 36642783
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
37. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
38. Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors.
Vaid AK; Deshmukh C; Rohatgi N; Ghosh J
Indian J Cancer; 2022 Mar; 59(Supplement):S130-S141. PubMed ID: 35343197
[TBL] [Abstract][Full Text] [Related]
39. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer risk and clinical implications for germline PTEN mutation carriers.
Ngeow J; Sesock K; Eng C
Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
